Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Anders Gülfe"'
Publikováno v:
BMC Musculoskeletal Disorders, Vol 21, Iss 1, Pp 1-8 (2020)
Abstract Background Surgical site infections are more frequent among patients with rheumatic disease. To what extent this is related to immunosuppressive antirheumatic drugs is unclear, as is the value of discontinuing medication perioperatively. The
Externí odkaz:
https://doaj.org/article/4723331837614313bfa39bf123c24cc3
Publikováno v:
BMC Musculoskeletal Disorders, Vol 21, Iss 1, Pp 1-8 (2020)
BMC Musculoskeletal Disorders
BMC Musculoskeletal Disorders
Background Surgical site infections are more frequent among patients with rheumatic disease. To what extent this is related to immunosuppressive antirheumatic drugs is unclear, as is the value of discontinuing medication perioperatively. The aim of s
Publikováno v:
Arthritis careresearch. 70(11)
Objective: To study the impact of common noncomposite disease activity measures on sick leave in biologics-treated patients with rheumatoid arthritis (RA). Methods: Data from study visits by biologics-treated RA patients of working age (
Autor:
Anders Gülfe, Tor Olofsson, Johan K. Wallman, Martin Neovius, Jonas Söderling, L.E. Kristensen
Publikováno v:
Oral Presentations.
Background Sick leave generally represents the earliest phase of work-loss in rheumatoid arthritis (RA) patients, often on the trajectory towards more permanent disability pension. Sick leave may still change with disease activity fluctuations and is
Autor:
Robin Christensen, Johan Karlsson, Tore Saxne, Pierre Geborek, Henning Bliddal, Lars Erik Kristensen, Anders Gülfe
Publikováno v:
Arthritis Care & Research. 66:173-179
ObjectiveTo study the impact of swollen to tender joint count ratio (STR) and other baseline characteristics on treatment response to a first course of anti-tumor necrosis factor (anti-TNF) therapy in rheumatoid arthritis (RA) patients. MethodsPatien
Publikováno v:
Scandinavian journal of rheumatology. 45(6)
Health utilities derived from answers to generic health-related quality of life (HRQoL) questionnaires such as the EuroQol 5-Dimensions (EQ-5D) are often used in cost-utility analyses (CUAs) of new and expensive treatments. Different preference sets
Autor:
Elisabet Lindqvist, Christine Wennerås, Anna Grankvist, Kristofer Andréasson, Jan Marsal, Göran Jönsson, Tore Saxne, Anders Gülfe, Ragnar Ingvarsson, Pia Lindell
Publikováno v:
Rheumatology. 54:369-371
Autor:
Anders Gülfe, Magnus Tägil, Philippe Kopylov, Pia Malcus Johnsson, Pierre Geborek, Anna-Lena Sturesson, Gunnel Sandqvist
Publikováno v:
Rheumatology. 51:2246-2251
Objectives. To explore the ability of six outcome measures to capture clinically important changes in patients with rheumatic diseases undergoing hand surgery and to study predictors of changes in activity performance in different patient and surgery
Publikováno v:
Gülfe, A, Wallman, J K & Kristensen, L E 2016, ' EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors : a prospective cohort study from southern Sweden ', Arthritis Research & Therapy, vol. 18, 51, pp. 1-7 . https://doi.org/10.1186/s13075-016-0950-0
Arthritis Research & Therapy
Arthritis Research & Therapy
BACKGROUND: The development of EuroQol-5 dimensions (EQ-5D) utility over time in rheumatoid arthritis (RA) patients, treated with biologics other than tumour necrosis factor inhibitors (TNFi), based on the standard British (UK) and the new Swedish (S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::049c115a54db3cd6eca51d2d427df99e
https://curis.ku.dk/ws/files/173986344/art_3A10.1186_2Fs13075_016_0950_0.pdf
https://curis.ku.dk/ws/files/173986344/art_3A10.1186_2Fs13075_016_0950_0.pdf
Autor:
Lars Erik Kristensen, Anders Gülfe, Ingemar F Petersson, Lennart T H Jacobsson, Pierre Geborek, Tore Saxne
Publikováno v:
Arthritis Care & Research. 62:1399-1406
To introduce a novel, simple, utility-based outcome measure, the number needed per quality-adjusted life year (QALY) gained (NNQ), and to apply it in clinical practice in anti-tumor necrosis factor (anti-TNF)-treated patients with rheumatoid arthriti